Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 18Neoplasm Metastasis 6Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Breast Cancer Female 1Advanced Breast Cancer 1

Interventions

ribociclib 1palbociclib 1abemaciclib 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HR+/HER2- Breast Cancer × abemaciclib × Clear all
NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting
1,056 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡